This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record.
Whether GLP-1 receptor agonists improve hard cardiovascular and kidney outcomes in cardio-renal-metabolic disease, rather than weight alone — read against the SELECT, FLOW and SUMMIT trials.
The full text now lives in the updated version linked above. This page is kept online so that existing links and bookmarks continue to work; its body was replaced to avoid publishing the same article at two addresses.
Information only — not investment advice, and not medical advice.
Uthando Nethemba 
Leave a comment